TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00391027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (Lantus®)
Description: Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Human Insulin (Exubera®)
Description: Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Study: NCT00577824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 10mcg, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
Study: NCT01916434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High PUFA Salmon Fillets
Description: High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustainable PUFA salmon
Description: 'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No salmon
Description: The placebo group will continue to consume their habitual diet.
Study: NCT04079816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00025
Description: Noninvasive pulse oximeter sensor
Study: NCT03785379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
Study: NCT02753062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine, rituximab
Description: subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
Study: NCT00752583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Description: Blood, urine and dialysate sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemodialysis
Description: Blood, urine and dialysate sampling
Study: NCT05423067

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral permanent occlusion of uterine arteries
Description: bilateral permanent Occlusion of uterine arteries through abdominal route
Study: NCT01257373

Intervention type: DEVICE
Intervention: Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent
Description: Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
Study: NCT03010787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: single ascending dose of V565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: Multiple dose
Study: NCT01938027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Laparoscopy-assisted transanal total mesorectal excision
Study: NCT01921166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene plus gonadotropins
Description: clomiphene plus gonadotropin ovulation induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide flare
Description: Leuprolide flare ovulation induction
Study: NCT03539627

Intervention type: DRUG
Intervention: Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]
Description: patients are to receive azilsartan medoxomil
Study: NCT04314206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VNRX-5024
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study: NCT00990132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation
Description: Nocturnal non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long term oxygen therapy
Description: LTOT established as per national guidelines
Study: NCT03878394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and balance exercises
Description: The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
Study: NCT02426164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine HCl, morphine, epinephrine, methylprednisolone
Description: Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
Study: NCT00283517

Intervention type: DRUG
Intervention: antipsychotics
Description: as prescribed
Study: NCT03201601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-chiro-inositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study: NCT02980484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active
Description: Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
Study: NCT00556140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day.
Study: NCT00270738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect training of the PFMs via transversus abdominis
Description: Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home exercise
Description: PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
Study: NCT01695707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: see Arm Description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for pioglitazone)
Description: see Arm Description
Study: NCT04187066

Intervention type: BEHAVIORAL
Intervention: mindset induction
Description: induction of a health mindset to measure changes in cue-dependent and goal-directed behavior

Intervention type: BEHAVIORAL
Intervention: mindset induction
Description: induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
Study: NCT02195479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab IV
Description: Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
Study: NCT01037452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate/magnesium hydroxide
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02094300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Dissection Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
Study: NCT00017693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
Study: NCT01870778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: 1 mg/mL solution in 6 mL vials

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution to serelaxin
Study: NCT02961998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients from experimental group will take celecoxib, except for sorafenib
Study: NCT03050723

Intervention type: DEVICE
Group type: OTHER
Intervention: Princess® FILLER
Description: Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
Study: NCT04103593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
Study: NCT03551158

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Cardiac imaging for the assessment of the left atrium anatomy and function.
Study: NCT04639895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper and Pencil
Description: The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The standard treatment protocol.
Study: NCT01715480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccosprouts® (Brassica Protection Products LLC) homogenate
Description: In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks.
Study: NCT01143558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyme Disease Xenodiagnosis
Description: Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
Study: NCT03785379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
Study: NCT03802747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90 Selective Internal Radiation Therapy (SIRT)
Description: Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90 Selective Internal Radiation Therapy (SIRT)
Description: Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
Study: NCT03785379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
Study: NCT04124705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armour® Thyroid
Description: Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
Study: NCT03802747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
Study: NCT03846466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration
Study: NCT03878394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and balance exercises with cognitive exercises
Description: The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
Study: NCT03846466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 SC/S
Description: SC / Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/M
Description: IV / Multiple administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/M
Description: IV / Multiple administration